Edgewise Therapeutics, Inc. (EWTX) shares jumped 19.94 percent on Wednesday, rising $4.34 to $26.08, after the company reported positive updates from its ongoing Phase 2 CIRRUS-HCM clinical trial of EDG-7500, an oral cardiac sarcomere modulator being developed for hypertrophic cardiomyopathy.
Edgewise Therapeutics was trading at $26.17, up from a previous close of $21.75 on the Nasdaq. The stock opened at $22.44 and traded between $22.16 and $27.08 during the session.
Trading volume reached about 2.36 million shares, compared with an average volume of roughly 1.29 million shares.
The stock's 52-week range stands between $10.60 and $30.48.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.